公开(公告)号：EP1632242A2

公开(公告)日：2006-03-08

申请号：EP05021931.0

申请日：2001-02-19

申请人： Pharmexa A/S

发明人： Birk, Peter ,  Jensen, Martin Roland ,  Nielsen, Klaus Gregorius

IPC分类号： A61K38/00 ,  A61K38/16 ,  A61K38/17

CPC分类号： G01N33/6896 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/19 ,  A61K39/00 ,  A61K39/0007 ,  A61K39/385 ,  A61K47/646 ,  A61K2039/53 ,  A61K2039/6037 ,  A61K2039/6087 ,  A61K2039/64 ,  C07K14/4711 ,  C07K2319/00 ,  G01N2333/4709 ,  G01N2500/04 ,  Y02A50/412 ,  A61K2300/00

摘要： Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of Aβ's B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

摘要翻译： 公开了以淀粉样沉积为特征的疾病的新型方法。 该方法通常依赖于抗淀粉样变蛋白（有助于形成淀粉样蛋白的蛋白）如β淀粉样蛋白（A 2）的免疫。 免疫优选通过施用自体淀粉样蛋白多肽的类似物来实现，所述类似物能够针对自体淀粉样蛋白多肽诱导抗体产生。 作为免疫原特别优选的是自体A 2，其通过引入一个或少数外来的免疫优势和混杂的T细胞表位而被修饰，同时基本上保留了大部分A 2的B细胞表位。 还公开了针对淀粉样变性多肽的核酸疫苗接种和使用活疫苗的疫苗接种以及可用于疫苗接种的方法和装置。 这样的方法和手段包括用于鉴定淀粉样蛋白生成蛋白质的有用免疫原性类似物的方法，用于制备类似物和药物制剂的方法，以及核酸片段，载体，转化细胞，多肽和药物制剂。